Reference links:
Office. (2019). Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to advance agency's continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-new-steps-advance-agencys-continued-evaluation
Office of the Commissioner. (2019). What to Know About Products Containing Cannabis and CBD? U.S. Food and Drug Administration. https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis
More Kroger Co. stores to carry CBD products. (2019, July 29). Supermarket News. https://www.supermarketnews.com/organic-natural/more-kroger-co-stores-carry-cbd-products
Kentucky CBD Laws: 2019 Legal Hemp Regulations in KY, US. (2019, November 6). HealthMJ. https://www.healthmj.com/cbd/states/kentucky/
Clinical Studies and Case Reports. (2019). Cannabis-Med.Org. https://www.cannabis-med.org/studies/study.php
Osborne, A.L., Solowij, N., & Weston-Green, K. (2017). A systematic review of the effect of cannabis-diol on cognitive function: Relevance to schizophrenia. Neuroscience & Biobehavioral Reviews, 72, 310-324. • Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015). Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics, 12(4), 699-730. https://doi.org/10.1007/s13311-015-0377-3
Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015). Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics, 12(4), 699–730. https://doi.org/10.1007/s13311-015-0377-3
Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215. https://doi.org/10.1038/sj.bjp.0707442
Bill Gurley, University of Arkansas for Medical Sciences, College of Pharmacy Content vs. Label Claim: A Survey of CBD Content in Commercially Available Products Accessed via a public hearing published on May 31, 2019 on fda.gov
1This image does not promote use of CBD products or vaping in any form. It is a mere representation of available forms of products and general guidelines for its use. We strongly recommend that the consumer must consult a healthcare provider and follow instructions given by a healthcare provider and/ or on the product label.
COOPERATIVE EXTENSION PROGRAM
KYSU.EDU/AG | @KYSUAG
Educational programs of Kentucky Cooperative Extension serve all people regardless of economic or social status and will not discriminate on the basis of race, color, ethnic origin, national origin, creed, religion, political belief, sex, sexual orientation, gender identity, gender expression, pregnancy, marital status, genetic information, age, veteran status, or physical or mental disability. Kentucky State University, University of Kentucky, U.S. Department of Agriculture, and Kentucky Counties, Cooperating. 2020 KYSU-CEP-FAC-0071